Literature DB >> 16866563

Progress in SPECT/CT imaging of prostate cancer.

Youngho Seo1, Benjamin L Franc, Randall A Hawkins, Kenneth H Wong, Bruce H Hasegawa.   

Abstract

Prostate cancer is the most common type of cancer (other than skin cancer) among men in the United States. Although prostate cancer is one of the few cancers that grow so slowly that it may never threaten the lives of some patients, it can be lethal once metastasized. Indium-111 capromab pendetide (ProstaScint, Cytogen Corporation, Princeton, NJ) imaging is indicated for staging and recurrence detection of the disease, and is particularly useful to determine whether or not the disease has spread to distant metastatic sites. However, the interpretation of 111In-capromab pendetide is challenging without correlated structural information mostly because the radiopharmaceutical demonstrates nonspecific uptake in the normal vasculature, bowel, bone marrow, and the prostate gland. We developed an improved method of imaging and localizing 111In-Capromab pendetide using a SPECT/CT imaging system. The specific goals included: i) development and application of a novel iterative SPECT reconstruction algorithm that utilizes a priori information from coregistered CT; and ii) assessment of clinical impact of adding SPECT/CT for prostate cancer imaging with capromab pendetide utilizing the standard and novel reconstruction techniques. Patient imaging studies with capromab pendetide were performed from 1999 to 2004 using two different SPECT/CT scanners, a prototype SPECT/CT system and a commercial SPECT/CT system (Discovery VH, GE Healthcare, Waukesha, WI). SPECT projection data from both systems were reconstructed using an experimental iterative algorithm that compensates for both photon attenuation and collimator blurring. In addition, the data obtained from the commercial system were reconstructed with attenuation correction using an OSEM reconstruction supplied by the camera manufacturer for routine clinical interpretation. For 12 sets of patient data, SPECT images reconstructed using the experimental algorithm were interpreted separately and compared with interpretation of images obtained using the standard reconstruction technique. The experimental reconstruction algorithm improved spatial resolution, reduced streak artifacts, and yielded a better correlation with anatomic details of CT in comparison to conventional reconstruction methods (e.g., filtered back-projection or OSEM with attenuation correction only). Images produced with the experimental algorithm produced a subjective improvement in the confidence of interpretation for 11 of 12 studies. There were also changes in interpretations for 4 of 12 studies although the changes were not sufficient to alter prognosis or the patient treatment plan.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16866563     DOI: 10.1177/153303460600500404

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  9 in total

1.  Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.

Authors:  David M Schuster; Bital Savir-Baruch; Peter T Nieh; Viraj A Master; Raghuveer K Halkar; Peter J Rossi; Melinda M Lewis; Jonathon A Nye; Weiping Yu; F DuBois Bowman; Mark M Goodman
Journal:  Radiology       Date:  2011-04-14       Impact factor: 11.105

Review 2.  Technological development and advances in single-photon emission computed tomography/computed tomography.

Authors:  Youngho Seo; Carina Mari; Bruce H Hasegawa
Journal:  Semin Nucl Med       Date:  2008-05       Impact factor: 4.446

3.  Combined SPECT and Multidetector CT for Prostate Cancer Evaluations.

Authors:  Carina Mari Aparici; David Carlson; Nhan Nguyen; Randall A Hawkins; Youngho Seo
Journal:  Am J Nucl Med Mol Imaging       Date:  2012

4.  Task Equivalence for Model and Human-Observer Comparisons in SPECT Localization Studies.

Authors:  Anando Sen; Faraz Kalantari; Howard C Gifford
Journal:  IEEE Trans Nucl Sci       Date:  2016-05-19       Impact factor: 1.679

5.  In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT.

Authors:  Youngho Seo; Carina Mari Aparici; Matthew R Cooperberg; Badrinath R Konety; Randall A Hawkins
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

Review 6.  Positron emission tomography imaging of prostate cancer.

Authors:  Hao Hong; Yin Zhang; Jiangtao Sun; Weibo Cai
Journal:  Amino Acids       Date:  2009-11-28       Impact factor: 3.520

Review 7.  The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients.

Authors:  Ashesh B Jani; Stanley L Liauw; Michael J Blend
Journal:  Clin Med Res       Date:  2007-06

8.  Novel targeted nuclear imaging agent for gastric cancer diagnosis: glucose-regulated protein 78 binding peptide-guided 111In-labeled polymeric micelles.

Authors:  Chun-Chia Cheng; Chiung-Fang Huang; Ai-Sheng Ho; Cheng-Liang Peng; Chun-Chao Chang; Fu-Der Mai; Ling-Yun Chen; Tsai-Yueh Luo; Jungshan Chang
Journal:  Int J Nanomedicine       Date:  2013-04-10

9.  Phyllanthus Suppresses Prostate Cancer Cell, PC-3, Proliferation and Induces Apoptosis through Multiple Signalling Pathways (MAPKs, PI3K/Akt, NFκB, and Hypoxia).

Authors:  Yin-Quan Tang; Indubala Jaganath; Rishya Manikam; Shamala Devi Sekaran
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-16       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.